SCHEMBL23539712

SCHEMBL23539712

N=C(NC(=S)Nc1cccc(C(F)(F)F)c1)c1cccc(Cl)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.70
▸ ALDH1A1 P00352 9/20 0.70
▸ MEN1 O00255 6/20 0.70
▸ KMT2A Q03164 6/20 0.70
▸ SMN1; SMN2 Q16637 5/20 0.70
▸ CYP1A2 P05177 2/20 0.70
▸ CYP3A4 P08684 2/20 0.70
▸ CYP2D6 P10635 2/20 0.70
▸ CYP2C19 P33261 2/20 0.70
▸ HTT P42858 4/20 0.66
▸ LMNA P02545 3/20 0.66
▸ NPSR1 Q6W5P4 5/20 0.58
▸ GAA P10253 4/20 0.58
▸ TDP1 Q9NUW8 2/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ POLB P06746 1/20 0.58
▸ CYP2C9 P11712 1/20 0.58
▸ XBP1 P17861 1/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ IDO1 P14902 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3053989 0.85 ALDH1A1 (0.80) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL30387868 0.83 MAPT (1.00) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL24169274 0.83 MAPT (1.00) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL23539356 0.82 RXFP1 (0.54) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL23539545 0.81 MEN1 (0.63) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL30041325 0.81 MEN1 (0.63) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7175227 0.77 MAPT (0.86) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL14096446 0.74 ALDH1A1 (0.69) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3059584 0.74 SMN1; SMN2 (0.69) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL30042809 0.74 MAPT (0.64) MAPTALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011315-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF PRISM MEDICINES, INC. 2025-01-09 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
US-20230295147-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF ARYL THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-20230295147-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF ARYL THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-20230295147-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF ARYL THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-11608329-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2023-03-21 — — US disclosed
US-20210230153-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF ARYL THERAPEUTICS, INC. 2021-07-29 — — US disclosed
US-20210230153-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF ARYL THERAPEUTICS, INC. 2021-07-29 — — US disclosed
WO-2021127301-A1 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS Ikena Oncology, Inc. (US) 2021-06-24 — — WO disclosed
WO-2021127301-A1 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS Ikena Oncology, Inc. (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011315-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF AHR, ARNT, HCAR1 MAPT 4673/4885ALDH1A1 289/4885MEN1 4851/4885
US-11608329-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof AHR, ARNT, HCAR1 MAPT 4673/4885ALDH1A1 289/4885MEN1 4851/4885
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof AHR, ARNT, HCAR1 MAPT 4673/4885ALDH1A1 289/4885MEN1 4851/4885
US-20230295147-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF AHR, ARNT, HCAR1 MAPT 4673/4885ALDH1A1 289/4885MEN1 4851/4885
US-20210230153-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF AHR, ARNT, HCAR1 MAPT 4673/4885ALDH1A1 289/4885MEN1 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback